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Abstract
Background: Intestinal mucosal S100A12 and myeloperoxidase (MPO) are inflammatory biomarkers in humans with
inflammatory bowel disease (IBD). However, these biomarkers have not been studied in the intestinal mucosa of
dogs with chronic enteropathies (CE), even though dogs with CE have increased S100A12 concentrations in feces
and serum. This study investigated mucosal S100A12 concentrations and MPO activities in both dogs with CE and
healthy Beagles. ELISA (S100A12 concentrations) and spectrophotometric methods (MPO activity) were used. The
associations of both biomarkers with canine IBD activity index (CIBDAI), histopathologic findings, clinical outcome,
and serum albumin concentrations were also investigated. We studied intestinal mucosal samples originating from
different intestinal regions of 40 dogs with CE and 18 healthy Beagle dogs (duodenum, ileum, colon, and cecum).
Results: Compared with healthy Beagles, mucosal S100A12 concentrations in dogs with CE were significantly
higher in the duodenum (p < 0.0001) and colon (p = 0.0011), but not in the ileum (p = 0.2725) and cecum (p = 0.
2194). Mucosal MPO activity of dogs with CE was significantly higher in the duodenum (p < 0.0001), ileum (p = 0.
0083), colon (p < 0.0001), and cecum (p = 0.0474). Mucosal S100A12 concentrations in the duodenum were significantly
higher if the inflammatory infiltrate consisted mainly of neutrophils (p = 0.0439) or macrophages (p = 0.037). Mucosal
S100A12 concentrations also showed a significant association with the severity of total histopathological injury and
epithelial injury in the colon (p < 0.05). Mucosal MPO activity showed a significant association (p < 0.05) with the severity
of total histopathological injury, epithelial injury, and eosinophil infiltration in the duodenum. There was no significant
association of both biomarkers with CIBDAI or clinical outcome.
Conclusions: This study showed that both mucosal S100A12 concentrations and MPO activities are significantly increased
in the duodenum and colon of dogs with CE; mucosal MPO was also increased in the ileum and cecum. Future research
should focus on assessing the clinical utility of S100A12 and MPO as diagnostic markers in dogs with CE.
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Background
Canine chronic enteropathy (CE) is a group of inflamma-
tory conditions of the intestinal tract with unknown
etiology [1]. Based on treatment response, canine CE is
defined as food-responsive diarrhea or enteropathy (FRD
or FRE), antibiotic-responsive diarrhea or enteropathy
(ARD or ARE), steroid-responsive diarrhea or enteropathy
(SRD or SRE), or steroid-non-responsive diarrhea or
enteropathy (SNRD or SNRE) [2, 3]. While the etiology
and pathogenesis of canine CE is not fully understood, an
aberrant immune response to antigens derived from
endogenous microbiota and diet is likely to play an
important role in canine CE pathogenesis [2, 4, 5]. There-
fore, phagocyte activation biomarkers may represent
potential and useful markers of inflammation in dogs with
CE. Accordingly, more research is needed to clarify the
roles of these markers in the pathogenesis of CE.
S100A12 (also known as calgranulin C) belongs to the
S100/calgranulin protein subfamily and is mainly
expressed and secreted by activated neutrophils [6, 7] and
macrophages/monocytes [8]. After S100A12 release into
the extracellular space, either due to cell damage or activa-
tion of phagocytes, S100A12 acts as a ligand for the
advanced glycation end products (RAGE) receptor [9, 10].
Binding to RAGE can induce sustained post-receptor
signaling, including activation of nuclear factor κB (NF-
κB) and the upregulation of transmembrane RAGE itself
which can in turn lead to amplification and perpetuation
of the inflammatory response [9–11]. S100A12 is a useful
biomarker in human patients with inflammatory diseases,
such as IBD [12–23]. S100A12 concentrations are
increased in fecal samples, serum, and intestinal mucosa
from human patients with IBD [12–19]. S100A12 concen-
trations are also increased in feces and serum from dogs
with CE [24–26]. In addition, increased fecal S100A12
concentrations in dogs with CE correlate with severity of
clinical signs, endoscopic lesions in the duodenum,
colonic inflammation, and negative outcome [24, 25].
Fecal S100A12 concentrations have also been measured in
dogs with different types of CE, including FRD, ARD,
SRD, and SNRD [26]. Increased fecal S100A12 concentra-
tions have been reported in dogs with SRD when com-
pared with dogs with FRD or ARD, but also in SNRD
dogs when compared to dogs in complete remission after
steroid treatment [26]. However, when measuring fecal
S100A12 concentrations, it is not possible to differentiate
the region of origin within the intestinal mucosa. Given
the various physiological and pathophysiological roles of
S100A12, it is reasonable to consider this protein’s func-
tion in the intestinal mucosa during inflammation in dogs
with CE.
Myeloperoxidase (MPO) is an enzyme found in neu-
trophils and at lower concentrations in macrophages/
monocytes and eosinophils [27–29]. Myeloperoxidase
generates hypochlorous acid (HOCl) from hydrogen per-
oxide (H2O2) and chloride and plays an important role
in intracellular microbial destruction [27–29]. However,
after phagocyte activation at an inflammatory site, MPO
is released into the extracellular space and induces oxi-
dative tissue damage of host tissue [30]. Increased muco-
sal MPO activity can be used as a biomarker of oxidative
stress and has been described in human patients with
IBD (both Crohn’s disease [CD] and ulcerative colitis
[UC]) [31–34] and also in animal models of human IBD
[35–37]. In our previous study, we measured mucosal
S100A12 concentrations and MPO activities in different
segments of the intestine of healthy Beagles (duodenum,
jejunum, ileum, and colon) [38]. However, to our know-
ledge, intestinal mucosal S100A12 concentrations and
MPO activities have not yet been investigated in dogs
with CE.
We hypothesized that mucosal S100A12 concentra-
tions and MPO activities are increased in dogs with CE
compared with healthy Beagles. We also assessed for any
possible association of intestinal mucosal S100A12 con-
centrations and MPO activities with histopathological
findings, canine inflammatory bowel disease activity
index (CIBDAI) scores, clinical outcome, or hypoalbu-
minemia in dogs with CE.
Methods
Study population
Dogs with chronic gastrointestinal signs
A total of 52 dogs with chronic gastrointestinal (GI)
signs such as vomiting, diarrhea, tenesmus, hematoche-
zia, or weight loss lasting more than 3 weeks were
enrolled into our study over a 4-year period. For each
dog, diagnostic tests were performed to exclude under-
lying gastrointestinal infections (e.g. giardiasis) and neo-
plasia or extraintestinal disorders. These tests included
complete blood count, serum biochemical analysis, fecal
examination for parasites, abdominal ultrasound, and
gastroduodenoscopy or colonoscopy (or both) with
biopsy and histopathological examination. All the tests
were performed at the Veterinary Teaching Hospital,
Faculty of Veterinary Medicine, University of Helsinki,
Finland. The diagnosis of chronic enteropathy (CE) was
based on previously published clinical, laboratory, endo-
scopic, and histopathologic criteria [39, 40]. Before start-
ing any treatment, all dogs with chronic GI signs
underwent endoscopic examination. The area of endos-
copy was selected based on the clinical signs. Intestinal
mucosal biopsies from dogs with chronic GI signs were
collected over a 4-year period and were stored at − 80 °C
for 1-4 years for S100A12 and MPO determinations.
The flow diagram (Fig. 1) shows the group distribution
of enrolled dogs into the study.
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Healthy beagles
Intestinal tissue samples from 18 healthy laboratory
Beagle dogs were used as controls. The samples were
collected during post-mortem examinations at the
conclusion of unrelated studies. The Beagle dogs were
housed according to the European Union guidelines in
indoor groups with access to outdoor runs. The indoor
environmental temperature was maintained between
15 °C and 24 °C. The dogs were exposed to both natural
and artificial light (from 7 AM to 4 PM) and were fed a
standard commercial diet. All dogs were considered
healthy based on history, physical examination, complete
blood count, serum biochemistry profile, fecal examin-
ation, and histologic evaluation. Intestinal mucosal sam-
ples were collected from four different segments of the
intestine. From all dogs (n = 18) duodenum, ileum, and
colon samples were provided; cecum samples were
obtained from six dogs (Fig. 1). All intestinal samples
from healthy Beagles were taken immediately after
euthanasia, snap-frozen in liquid nitrogen and stored at
− 80 °C for 4-7 years and 1-4 years for S100A12 and
MPO determinations, respectively.
Ethical statement
The clinical trial involving dogs with CE was prospectively
planned and all procedures were carried out under an eth-
ical approval granted by the Finnish National Animal
Experiment Board (study license No. ESAVI/6973/04.10.
03/2011 and ESAVI/10384/04.10.07/2014). Informed
owner consent was obtained at the time the dogs were
enrolled for gastroduodenoscopy, colonoscopy, or both.
The samples from healthy Beagles were collected during
post-mortem examinations after finalizing unrelated stud-
ies. These studies were approved by the Finnish National
Animal Experiment Board (study license No. ESLH-2007-
09833/Ym-23, ESAVI 2010-04178/Ym-23, and ESAVI/
7290/04.10.03/2012). All sections of this report adhere to
the ARRIVE Guidelines for reporting animal research
[41]. A completed ARRIVE guidelines checklist is included
in Checklist S1.
Clinical disease activity in dogs with chronic
enteropathies
The clinical disease activity in dogs with CE was deter-
mined based on the CIBDAI scoring system at the time
of study start and after treatment [42]. CIBDAI was
assessed using six prominent GI signs (ie, attitude and
activity, appetite, vomiting, stool consistency, stool fre-
quency, and weight loss); scores are based on severity
and range from 0 to 3. The total CIBDAI score repre-
sents the sum of all individual scores and was classified
as insignificant (score 0-3), mild (score 4-5), moderate
(score 6-8), or severe (score ≥ 9). Recording the CIBDAI
score before and after treatment was only possible in 30
of 40 dogs with CE, and was based on either available
scores taken by the responsible clinician before and after
treatment (in 13/30 and 5/30 of dogs, respectively) or
calculated retrospectively by the investigators (in 17/30
and 25/30 of dogs, respectively). For retrospectively
calculated scores, information was obtained from clinical
history (before treatment) and phone interviews with the
owners (after treatment). The treatment follow up of pa-
tients were not based on a standardized time frame and
the second CIBDAI was either based on control visits or
phone calls at least 2 weeks apart from the start of the
treatment. The CE type was determined by response to
treatment and since not all included dogs developed
diarrhea as a clinical sign, the CE type was defined as
FRE, ARE, SRE, and SNRE [2, 3]. As antibiotic, Tylosin
at a dose of 25 mg/kg/day for 7 days was mainly used
[43]. In some canine patients also metronidazole with/
without enrofloxacin was used. For all three SNRE dogs,
anallergenic diet (Royal Canin®) was started first,
followed by antibiotic trial and consecutive prednisolone
in two, but immediate prednisolone in the third dog. All
Fig. 1 Flow diagram of enrolled dogs. Flow diagram showing group distribution and inclusion and exclusion criteria of all dogs enrolled in the
study. CE: chronic enteropathies
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owners opted for euthanasia due to severity of clinical
signs and unfavorable response.
Serum albumin concentrations in dogs with chronic
enteropathies
The serum albumin concentration was determined in each
dog with CE. A serum albumin concentration < 20 g/L
was considered hypoalbuminemic [1].
Histopathological examination
Histopathological assessment of mucosal tissue samples
from canine patients and healthy Beagles collected by en-
doscopy or during necropsy was performed. The samples
were fixed in 4% formaldehyde solution in phosphate-
buffered saline, embedded in paraffin, sectioned (3-5 μm),
and stained with hematoxylin and eosin (HE). Histopatho-
logical changes of the samples were evaluated and scored
by a single pathologist (PS) using the guidelines of the
World Small Animal Veterinary Association (WSAVA)
Gastrointestinal Standardization Group [39, 40]. In every
case, the pathologist was blinded to the results of clinical
and laboratory examinations and to mucosal levels of
S100A12 and MPO. The severity of histopathological
changes in different regions of the intestine was evaluated
and scored as normal (0), mild (1), moderate (2), or severe
(3) according to the WSAVA standardization guidelines.
The total histopathological injury score was defined as the
sum of the morphology and inflammatory scores and was
classified as insignificant (total score 0-4), mild (total score
5-9), moderate (total score 10-14), severe (total score 15-
19), or very severe (total score ≥ 20). The samples from
ileum and cecum were examined and scored using the
guidelines provided for the interpretation of duodenal and
colonic biopsies, respectively; this was performed because
of the absence of specific templates for these intestinal
segments in the WSAVA Gastrointestinal Standardization
Group guidelines [39, 40].
Measurement of mucosal S100A12 concentration
Snap-frozen intestinal mucosal samples from dogs with CE
and healthy Beagles were homogenized using a Polytron
homogenizer in ice-cold extraction buffer (containing
50 mM Tris/HCl base, 150 mM NaCl, 10 mM CaCl2, 0.
2 mM NaN3 and 0.01% (v/v) Triton X-100; pH 7.6) in the
presence of EDTA-free protease inhibitor cocktail tablets (1
tablet/10 ml of extraction buffer) at a 20:1 ratio of extrac-
tion buffer to tissue. After homogenization, samples were
centrifuged at 13000 g at 4 °C for 10 min. Supernatants
were collected and stored at − 80 °C until assayed for
S100A12 concentration. S100A12 concentrations were
measured using an ELISA method as previously described
[38, 44]. In brief, immunoassay plates were coated with
200 ng/well of affinity-purified polyclonal anti-canine
S100A12 antibody and were blocked with 25 mM Tris-
buffered saline (TBS), 150 mM NaCl, 0.05% (v/v)
polyoxyethylene-20 sorbitan monolaurate, and 10% (w/v)
bovine serum albumin (BSA) at pH 8.0. Plates were then
incubated with duplicates of standard purified canine
S100A12 solutions, assay controls, or mucosal extracts
diluted in 25 mM TBS, 150 mM NaCl, 0.05%
polyoxyethylene-20 sorbitan monolaurate, and 0.5% (w/v)
BSA at pH 8.0. To detect captured antigen, plates were
incubated with horseradish peroxidase-labeled anti-canine
S100A12 polyclonal antibody (15 ng/well) and developed
with a stabilized 3,3′,5,5′-tetramethylbenzidine substrate
(TMB). After a 5-min incubation with TMB, color develop-
ment was stopped with 4 M acetic acid and 0.5 M sulfuric
acid. Absorbance was measured at 450 nm. The researcher
(PG) was blinded to the individual dogs’ clinical data (ie,
health status, clinical outcome, and intestinal segment).
The lower detection limit of the ELISA assay for canine
S100A12 was determined by calculating the mean response
+ 3 times the standard deviation (SD) for 20 replicates of
the blank solution. S100A12 concentrations in extracts of
snap-frozen intestinal mucosal tissues were measured using
the same lot of reagents for all samples and are reported as
μg/L of the intestinal mucosal supernatant.
Measurement of mucosal myeloperoxidase activity
To measure mucosal MPO activity, snap-frozen intes-
tinal mucosal samples from healthy Beagles and dogs
with CE were weighed, suspended in ice-cold extraction
buffer at a 20:1 ratio of extraction buffer to tissue, and
homogenized as previously described [38]. After
homogenization, samples were centrifuged at 4000 g at
4 °C for 20 min. The supernatants were collected and
stored at − 80 °C. MPO activity was determined in
intestinal mucosa as previously described [38]. Briefly,
5 μL of supernatant and 5 μL of distilled water were
added to the reaction mixture containing 170 μL of
sodium phosphate buffer (80 mM, pH 5.4) with hexade-
cyltrimethylammonium bromide (HTAB, 0.5% w/v) and
3,3′,5,5′-tetramethylbenzidine (1.6 mmol/L). The mix-
ture was then incubated for 6 min at 37 °C, after which
20 μL of H2O2 (0.3 mmol/L) was added. After the
addition of H2O2, a kinetic measurement for 60 s was
started at a wavelength of 620 nm using an automated
biochemical analyzer (Konelab 30i, Thermo Fisher
Scientific, Vantaa, Finland). The researchers performing
the laboratory analysis (MH and SS) were blinded to
the individual dog’s clinical data (ie, health status, clin-
ical outcome, and intestinal segment). The lower detec-
tion limit of the spectrophotometric assay for mucosal
MPO was calculated based on the following formula:
mean blank + 3 × SD for 7 replicates of the blank solu-
tion. MPO activity was expressed as the delta absorb-
ance units per minute (ΔA/min) in 5 μL of supernatant.
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Statistical analysis
To satisfy the assumptions of normality and the homogen-
eity of variances, the original values of S100A12 and MPO
were transformed to a logarithmic scale. The normality of
log-transformed values was then confirmed by Shapiro-
Wilk test. The differences between S100A12 concentra-
tions and MPO activities in different intestinal segments
(duodenum, ileum, colon, and cecum) between dogs with
CE and healthy Beagles were determined using Student’s
t-tests. An analysis of variance (ANOVA) test was used to
determine the association between S100A12 concentra-
tions and MPO activities with total histopathological
injury severity (insignificant, mild, moderate, or severe)
and individual histopathological changes severity (normal,
mild, moderate, or severe). A Spearman’s correlation
coefficient was used to determine a potential correlation
between S100A12 concentrations and MPO activities in
dogs with CE and healthy Beagles. A possible correlation
between CIBDAI score and S100A12 concentrations or
MPO activities was tested using linear regression. The
generalized logit-model was used to determine a possible
association between S100A12 concentrations and MPO
activities with clinical outcome (ie, FRE, ARE, SRE, or
SNRE) in dogs with CE. All statistical differences were cal-
culated based on the log-transformed values of S100A12
and MPO, and presented as mean and standard deviation
in figures. However, untransformed values are presented
as median (interquartile range: IQR) or median (range) as
appropriate, for ease of interpretation in tables and texts.
No adjustment was made for multiple comparisons in
this study. For all analyses, we considered values of p < 0.
05 as significant. All statistical analyses were performed
using SAS 9.3 statistical software (SAS Institute Inc., Cary,
NC, USA).
Results
Study population
Dogs with CE and healthy Beagles had a median age of
5 years (range 1-13 years) and 10.5 years (range 6-13 years),
respectively. In the CE group, five dogs were intact females,
nine dogs were spayed females, 15 dogs were intact males,
and 11 dogs were castrated males. In the healthy Beagle
control group, 10 dogs were intact females and eight dogs
were intact males. The breeds of dogs with CE were the
following: six mixed breed dogs, two German Shepherd
dogs, two Parson Russell Terriers, two Shetland Sheepdogs,
two Standard Poodles, two Rottweilers, and two Rough
Collies. In addition, there were one of each of the following:
Alaskan Malamute, Bichon Frise, Border Terrier, Chow
Chow, Dalmatian, English Bulldog, Golden Retriever,
Havanese, Irish Terrier, Jack Russell Terrier, Long-haired
Dachshund, Mudi, Norwegian Lundehund, Rhodesian
Ridgeback, Siberian Husky, Silky Terrier, Smooth Collie,
Spanish Water Dog, Staffordshire Bull Terrier, Toy Poodle,
West Highland White Terrier, and White Shepherd dog.
Out of 52 dogs, 12 dogs with chronic GI signs were
excluded from further analysis. Seven dogs had gastrointes-
tinal neoplasia (ie, 3 gastric adenocarcinomas, 2 lymphomas,
1 rectal plasma cell tumor, and 1 rectal adenocarcinoma).
Four dogs had primary esophageal disorders, and one dog
was positive for Giardia on fecal examination. A total of 40
dogs with CE were included in the study for analysis.
Twenty-five dogs underwent gastroduodenoscopy, 10 dogs
had both gastroduodenoscopy and colonoscopy, and colon-
oscopy alone was performed in 5 dogs. Sixty-eight intestinal
mucosal biopsies were collected by endoscopy from four dif-
ferent segments of the intestinal tract of above-mentioned
dogs, namely duodenum (n = 35), ileum (n = 12), colon (n =
15), and cecum (n= 6). Group distribution and inclusion/ex-
clusion criteria of all dogs enrolled in this study are shown
in Fig. 1.
Mucosal S100A12 concentrations
Mucosal S100A12 concentrations in each intestinal
segment in dogs with CE and healthy Beagles are shown
in Fig. 2. The mucosal S100A12 concentrations in dogs
with CE were significantly higher than those in healthy
Beagles in the duodenum (43.93 [23.62–78.03] vs. 11.86
[7.66–29.1] μg/L; p < 0.0001) and colon (63.04 [33.53–211.
53] vs. 15.94 [6.95–59.3] μg/L; p = 0.0011). Even though
dogs with CE had higher mucosal S100A12 concentra-
tions than healthy Beagles in the ileum (118.54 [47.26-142.
9] vs. 48.1 [24.87-91.4] μg/L; p = 0.2725) and cecum (160.
38 [43.27-326.28] vs. 33.53 [27.97-38.01] μg/L; p = 0.2194),
these differences did not reach statistical significance. The
lower detection limit of the ELISA assay for mucosal
S100A12 was 0.2 μg/L.
Mucosal myeloperoxidase activity
Mucosal MPO enzyme activity in each intestinal segment
in dogs with CE and healthy Beagles are shown in Fig. 3.
The mucosal MPO activity of dogs with CE was signifi-
cantly higher than the corresponding activity in healthy
Beagles in the duodenum (1.3 [0.77–2.16] vs. 0.41 [0.11–0.
64] ΔA/min; p < 0.0001), ileum (1.91 [0.72–2.83] vs. 0.75
[0.21–1.27] ΔA/min; p = 0.0083), colon (1.46 [0.57–3.01
vs. 0.09 [0.03–0.17] ΔA/min; p < 0.0001] ΔA/min), and
cecum (0.68 [0.3–1.55] vs. 0.19 [0.08–0.4] ΔA/min; p = 0.
0474). The lower detection limit of the spectrophotomet-
ric assay for mucosal MPO was 0.004 ΔA/min.
Mucosal S100A12 concentrations and MPO activities in
relation to histopathologic changes
Mucosal S100A12 concentrations showed a significant
association with the severity of macrophage infiltration in
the duodenum of dogs with CE (Table 1, p = 0.0439). In
addition, the duodenal mucosal S100A12 concentrations
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were significantly higher if the inflammatory infiltrate con-
tained neutrophils 61.1 [19.51-179.60] vs. 42.72 [7.41-102.
46] μg/L; p = 0.037). However, when S100A12 concentra-
tions were compared among the severity groups (normal,
mild, moderate, and severe) of neutrophilic infiltration in
the duodenum, we did not find a significant association in
dogs with CE (Table 1, p = 0.1542). However, mucosal
S100A12 concentrations were numerically higher in those
with mild, moderate, or severe neutrophilic infiltration
than in those with no neutrophilic infiltration. In addition,
no significant association was found between S100A12
concentrations and severity of neutrophilic infiltration in
the ileum, colon, and cecum of dogs with CE. In the colon,
mucosal S100A12 concentrations showed a significant
association with the severity of epithelial injury and total
histopathologic injury (Table 2, p < 0.05). Higher mucosal
MPO activity showed a significant association with sever-
ity of total histopathologic injury, epithelial injury, and eo-
sinophilic infiltration in the duodenum (Table 1, p < 0.05).
In the duodenum of dogs with CE, mucosal MPO activity
was numerically higher in samples with moderate and se-
vere neutrophilic infiltration than in samples with mild or
no neutrophilic infiltration (Table 1). However, these dif-
ferences did not reach statistical significance (p = 0.7326).
Based on the histological examination of intestinal sam-
ples from healthy Beagles, the median total WSAVA score
of all samples was 0 (range 0–4), classifying all findings as
insignificant.
Mucosal S100A12 concentrations and MPO activities in
relation to CIBDAI and clinical outcome
Based on treatment response after diet change or anti-
biotic or corticosteroid therapy, the outcomes of 30 dogs
with CE were classified as follows: FRE (n = 10), ARE (n
= 4), SRE (n = 13), and SNRE (n = 3). The median CIBDAI
scores before and after treatment and the type of clinical
outcome are summarized in Table 3. In dogs with CE, we
did not observe any significant association between muco-
sal S100A12 concentrations or MPO activities with CIBDAI
Fig. 2 Scatter plot displaying log-transformed intestinal mucosal S100A12 concentrations in CE dogs and healthy Beagles. Data are expressed as
the mean ± standard deviation. Individual data points are shown by triangles (samples from healthy Beagles) and circles (samples from CE dogs).
CE: chronic enteropathies; **p < 0.01 vs. healthy colon; #p < 0.0001 vs. healthy duodenum
Fig. 3 Scatter plot displaying log-transformed intestinal mucosal MPO activity in CE dogs and healthy Beagles. Data are expressed as the mean ±
standard deviation. Individual data points are shown by triangles (samples from healthy Beagles) and circles (samples from CE dogs) CE: chronic
enteropathies; *p < 0.05 vs. healthy cecum; **p < 0.01 vs. healthy ileum; #p < 0.0001 vs. healthy duodenum and colon
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Table 1 Mucosal S100A12 and MPO levels in relation to histopathologic changes in the duodenum and ileum
Histopathological findings n Severity groups S100A12 (μg/L)
Median (IQR)
P valuea MPO (ΔA/min)
Median (IQR)
P valuea
Duodenum 35
Total histopathological severity 35 Insignificant (n = 16) 33.65 (7.41-155.9) 0.2240 0.9 (0.2-2.95) 0.006b
Mild (n = 15) 53.12 (10.07-164.85) 1.49 (0.14-4.55)
Moderate (n = 4) 52.22 (42-179.6) 7.54 (0.94-17.16)
Morphological criteria 35
Villus stunting 35 Normal (n = 20) 44.18 (7.41-155.9) 0.4090 1.23 (0.14-4.55) 0.1439
Mild (n = 10) 45.02 (19.51-179.6) 1.21 (0.37-3.88)
Moderate (n = 3) 56.27 (42.72-164.85) 2.16 (1.63-11.62)
Severe (n = 2) 26.04 (10.07-42) 8.85 (0.54-17.16)
Epithelial injury 35 Normal (n = 30) 48.68 (7.41-164.85) 0.9122 1.23 (0.14-11.62) 0.0455b
Mild (n = 3) 28.94 (19.51-179.6) 1.58 (0.94-2.9)
Moderate (n = 2) 34.38 (26.76-42) 9.82 (2.48-17.16)
Crypt distension 35 Normal (n = 29) 42.96 (7.41-164.85) 0.4156 1.29 (0.14-17.16) 0.0694
Mild (n = 5) 67.87 (19.75-179.6) 0.94 (0.63-1.63)
Moderate (n = 1) 42.72 11.62
Lacteal dilation 35 Normal (n = 19) 28.94 (7.41-155.9) 0.0889 1.24 (0.2-17.16) 0.0708
Mild (n = 10) 54.7 (12.49-144.29) 1.07 (0.14-2.48)
Moderate (n = 6) 53.07 (42.72-179.6) 2.81 (0.94-11.62)
Mucosal fibrosis 35 Normal (n = 31) 42.96 (7.41-179.6) 0.9191 1.36 (0.14-17.16) 0.6993
Mild (n = 4) 63.88 (10.07-93.02) 0.83 (0.54-3.88)
Inflammatory criteria 35
Intraepithelial lymphocytes 35 Normal (n = 23) 42.96 (7.41-164.85) 0.9381 1.24 (0.14-17.16) 0.7695
Mild (n = 10) 36.44 (11.53-179.6) 1.12 (0.37-4.55)
Moderate (n = 2) 53.07 (44.42-61.71) 2.41 (1.36-3.46)
Lamina propria LPC 35 Normal (n = 2) 99.19 (42.48-155.9) 0.1963 0.53 (0.2-0.87) 0.0975
Mild (n = 15) 24.83 (7.41-164.85) 1.24 (0.36-2.95)
Moderate (n = 15) 50.94 (10.07-179.6) 1.36 (0.14-11.62)
Severe (n = 3) 61.71 (42-93.02) 3.46 (0.77-17.16)
Lamina propria eosinophils 35 Normal (n = 22) 58.99 (10.07-179.6) 0.0516 0.92 (0.14-3.46) 0.0004b
Mild (n = 5) 19.75 (7.41-42.96) 0.91 (0.64-2.95)
Moderate (n = 8) 43.33 (26.76-78.03) 3.39 (1.22-17.16)
Lamina propria neutrophils 35 Normal (n = 20)
Mild (n = 7)
Moderate (n = 6)
Severe (n = 2)
42.72 (7.41-102.46)
61.1 (19.51-155.9)
47.92 (24.83-179.6)
113.28 (61.71-164.85)
0.1542 1.07 (0.36-17.16)
1.49 (0.2-3.88)
1.4 (0.14-11.62)
2.81 (2.16-3.46)
0.7326
Lamina propria macrophage 35 Normal (n = 32) 42.84 (7.41-164.85) 0.0439b 1.39 (0.14-17.16) 0.1786
Mild (n = 3) 155.9 (44.2-179.6) 0.94 (0.2-1.36)
Ileum 12
Total histopathological severity 12 Insignificant (n = 8) 106.93 (9.59-317.21) 0.9816 1.91 (0.34-2.83) 0.3260
Mild (n = 4) 125.92 (16.36-151.79) 2.3 (0.79-7.01)
Morphological criteria 12
Villus stunting 12 Normal (n = 7) 120.84 (9.59-317.21) 0.7443 2.04 (0.34-2.83) 0.3447
Mild (n = 5) 116.24 (16.36-151.79) 1.77 (0.69-7.01)
Epithelial injury 12 Normal (n = 10) 118.54 (9.59-317.21) 0.4956 1.91 (0.34-3.23) 0.2387
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scores before treatment or the clinical outcome in each
intestinal segment (data not shown, p > 0.05).
Steroid non-responsive dogs (SNRE, n = 3) were eutha-
nized because of severe clinical signs and unfavorable
response to treatments. The median (range) of CIBDAI
score before treatment was higher in SNRE dogs (n = 3)
than in SRE dogs (n = 13) (7 [4–9] vs. 4 [0-7]). One SNRE
dog and two SRE dogs had hypoalbuminemia (< 20 g/L).
The median (range) of total histopathological injury score
of SNRE dogs was 7 (5-7) and SRE dogs was 6 (1-11). The
median (range) of mucosal S100A12 concentrations and
MPO activities in SNRE dogs compared to SRE dogs were
as follows in the duodenum: 53.12 (19.51-93.02) μg/L vs.
42.97 (12.49-179.6) μg/L and 1.22 (0.77-1.58) ΔA/min vs.
1.21 (0.14-17.6) ΔA/min, respectively.
Mucosal S100A12 concentrations and MPO activities in
relation to hypoalbuminemia in dogs with CE
Out of 40 dogs, 36 (90%) had normoalbuminemia with a
median (range) serum albumin concentration of 32.7 g/L
(24.9-39 g/L). However, four dogs (10%) had hypoalbu-
minemia with a median (range) serum albumin concentra-
tion of 12.2 g/L (11-13 g/L). Duodenal mucosal biopsies
were taken from the four hypoalbuminemic dogs and
mucosal S100A12 concentrations and MPO activities were
evaluated. The mucosal S100A12 concentrations and
MPO activities in hypoalbuminemic dogs with CE com-
pared to normoalbuminemic dogs were as follows: 128.94
[69.54-175.91] g/L vs. 42.72 [23.62-61.1] g/L and 1.55 [0.
81-3.14] ΔA/min vs. 1.58 [0.81-2.9] ΔA/min, respectively.
Since the number of hypoalbuminemic dogs was too low
for meaningful statistical analysis, we reported the results
descriptively.
Correlation between S100A12 concentrations and MPO
activities
A moderate positive correlation between mucosal S100A12
concentrations and MPO activities was seen in dogs with
CE and healthy Beagles combined (r = 0.392; p < 0.0001);
this correlation was also observed in healthy Beagles alone
(r= 0.327; p = 0.011). However, there was no correlation be-
tween mucosal S100A12 concentrations and MPO activities
in dogs with CE alone (p = 0.273) or in the different intes-
tinal segments from dogs with CE (duodenum: p = 0.0949;
ileum: p = 0.245; colon: p = 0.265; cecum: p = 0.325).
Discussion
To our knowledge, this paper is the first to report mucosal
S100A12 concentrations and MPO activities in the intes-
tines of dogs with CE. We observed that the mucosal
Table 1 Mucosal S100A12 and MPO levels in relation to histopathologic changes in the duodenum and ileum (Continued)
Histopathological findings n Severity groups S100A12 (μg/L)
Median (IQR)
P valuea MPO (ΔA/min)
Median (IQR)
P valuea
Moderate (n = 2) 84.07 (16.36-151.79) 4.18 (1.36-7.01)
Crypt distension 12 Normal (n = 11) 116.24 (9.59-317.21) 0.6913 2.04 (0.34-7.01) 0.4692
Moderate (n = 1) 120.84 0.79
Lacteal dilation 12 Normal (n = 8) 106.93 (9.59-317.21) 0.9881 1.56 (0.34-2.83) 0.2034
Mild (n = 4) 125.92 (16.36-162.43) 2.63 (0.79-7.01)
Mucosal fibrosis 12 Normal (n = 12) 118.54 (9.59-317.21) – 1.91 (0.34-7.01) –
Inflammatory criteria 12
Intraepithelial lymphocytes 12 Normal (n = 6) 109.23 (9.59-162.43) 0.6809 1.42 (0.34-2.81) 0.1787
Mild (n = 6) 123.62 (16.36-317.21) 2.3 (0.69-7.01)
Lamina propria LPC 12 Normal (n = 4) 118.78 (47.08-162.43) 0.5561 2.12 (0.44-2.81) 0.9999
Mild (n = 4) 68.6 (9.59-317.21) 1.81 (0.34-7.01)
Moderate (n = 4) 123.62 (47.32-151.79) 1.56 (0.69-3.23)
Lamina propria eosinophils 12 Normal (n = 9) 130.99 (9.59-317.21) 0.2514 1.77 (0.34-3.23) 0.2019
Mild (n = 2) 72.35 (47.08-97.62) 1.63 (0.44-2.81)
Moderate (n = 1) 16.36 7.01
Lamina propria neutrophils 12 Normal (n = 9) 116.24 (9.59-317.21) 0.7430 2.04 (0.34-3.23) 0.5989
Mild (n = 3) 120.84 (16.36-151.79) 1.36 (0.79-7.01)
Lamina propria macrophage 12 Normal (n = 12) 118.54 (9.59-317.21) – 1.91 (0.34-7.01) –
Association between mucosal S100A12 concentrations and MPO activities with severity of histopathological findings in the duodenum and ileum of dogs with CE.
Statistical differences were calculated based on the log-transformed values of S100A12 and MPO. Untransformed values are reported as median (IQR)
n sample size, IQR interquartile range, LPC lymphocytes/plasma cells
aANOVA test after logarithmic transformation of original values
bstatistically significant association
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Table 2 Mucosal S100A12 and MPO levels in relation to histopathologic changes in the colon and cecum
Histopathological findings n Severity groups S100A12 (μg/L)
Median (IQR)
P valuea MPO (ΔA/min)
Median (IQR)
P valuea
Colon 15
Total histopathological severity 15 Insignificant (n = 7) 49.01 (10.8-184.68) 0.0274b 1.04 (0.22-3.37) 0.1280
Mild (n = 7) 111.4 (32.81-538.8) 1.49 (0.38-4.08)
Moderate (n = 1) 1296.65 6.61
Morphological criteria 15
Epithelial injury 15 Normal (n = 8) 44.18 (10.8-184.68) 0.0083b 1.28 (0.22-4.08) 0.4232
Mild (n = 3) 254.57 (89.16-536.8) 1.49 (0.57-2.59)
Moderate (n = 3) 111.4 (32.81-211.53) 0.68 (0.38-3.01)
Severe (n = 1) 1296.65 6.61
Crypt hyperplasia 15 Normal (n = 11) 89.61 (10.8-536.8) 0.8412 1.1 (0.22-3.37) 0.3437
Mild (n = 3) 33.53 (32.81-1296.65) 1.46 (0.68-6.61)
Moderate (n = 1) 44.9 4.08
Crypt dilation and distorsion 15 Normal (n = 12) 76.01 (10.8-536.8) 0.5706 1.48 (0.22-4.08) 0.5858
Mild (n = 3) 49.01 (32.81-1296.65) 1.1 (0.68-6.61)
Mucosal fibrosis and atrophy 15 Normal (n = 8) 53.97 (10.8-1296.65) 0.4267 0.86 (0.22-6.61) 0.9124
Mild (n = 5) 111.4 (43.45-254.57) 2.59 (0.38-3.37)
Moderate (n = 1) 536.8 1.49
Severe (n = 1) 33.53 1.46
Inflammatory criteria 15
Lamina propria LPC 15 Normal (n = 2) 312.98 (89.16-536.8) 0.0554 1.03 (0.57-1.49) 0.4088
Mild (n = 9) 49.01 (22.89-211.53) 1.1 (0.22-3.37)
Moderate (n = 3) 44.9 (10.8-254.57) 2.59 (0.28-4.08)
Severe (n = 1) 1296.65 6.61
Lamina propria eosinophils 15 Normal (n = 9) 63.04 (10.8-254.57) 0.1076 1.04 (0.22-3.37) 0.1516
Mild (n = 3) 33.53 (22.89-89.16) 1.46 (0.57-2.04)
Moderate (n = 3) 536.8 (44.9-1296.65) 4.08 (1.49-6.61)
Lamina propria neutrophils 15 Normal (n = 10) 46.96 (10.8-1296.65) 0.2448 1.07 (0.22-6.61) 0.9400
Mild (n = 4) 161.47 (33.53-254.57) 2.02 (0.38-3.01)
Moderate (n = 1) 536.8 1.49
Lamina propria macrophage 15 Normal (n = 15) 63.04 (10.8-1296.65) – 1.46 (0.22-6.61) –
Cecum 6
Total histopathological severity 6 Insignificant (n = 6) 160.38 (8.62-405.48) – 0.68 (0.12-1.66) –
Morphological criteria 6
Epithelial injury 6 Normal (n = 3) 34.02 (8.62-249.74) 0.2187 0.37 (0.12-1.66) 0.4642
Mild (n = 3) 351.79 (71.02-405.48) 0.97 (0.4-1.51)
Crypt hypeplasia 6 Normal (n = 5) 71.02 (8.62-351.79) 0.3225 0.97 (0.12-1.66) 0.7163
Mild (n = 1) 405.48 0.4
Crypt dilation and distorsion 6 Normal (n = 5) 249.74 (8.62-405.48) 0.5229 0.98 (0.37-1.66) 0.0715
Mild (n = 1) 34.02 0.12
Mucosal fibrosis and atrophy 6 Normal (n = 6) 160.38 (8.62-405.48) – 0.68 (0.12-1.66) –
Inflammatory criteria 6
Lamina propria LPC 6 Normal (n = 2) 211.41 (71.02-351.79) 0.6222 1.24 (0.97-1.51) 0.2594
Mild (n = 4) 141.88 (8.62-405.48) 0.38 (0.12-1.66)
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S100A12 concentrations are significantly higher in dogs
with CE than in healthy Beagles in the duodenum and
colon. In the ileum and cecum, mucosal S100A12 concen-
trations were numerically higher in dogs with CE than
those in healthy Beagles. However, this difference did not
reach statistical significance. For the categories ileum and
cecum which have currently the lowest case numbers,
there would be the need for 95 and 27 dogs per group,
respectively, to achieve 80% power. The results of our
investigation in the duodenum are consistent with those
from Leach et al. in humans with IBD [18]. In that study,
duodenal and cecal biopsies from children with IBD
(including UC, CD, or unclassified IBD) were cultured
and supernatants were collected for ELISA determination
of S100A12 concentrations. Similar to our results, chil-
dren with UC, CD, or unclassified IBD had significantly
higher S100A12 concentrations in the culture superna-
tants of duodenal and cecal mucosal biopsies than those
in non-IBD control children [18]. In another similar study
in humans, Foell et al. also found higher S100A12 concen-
trations in culture supernatants of colonic and ileal biopsy
samples in patients with active CD than in those patients
with inactive CD or healthy controls [15]. In addition,
higher S100A12 concentrations were found in culture su-
pernatants of colonic samples in patients with active UC
than in those patients with inactive UC or healthy con-
trols. Similar to Foell et al. [15], we found significantly
higher S100A12 concentrations in colonic samples from
dogs with CE than those in healthy Beagles. However, in
contrast to people with CD, despite higher mucosal
S100A12 concentrations in ileal samples of dogs with CE
compared with healthy Beagles, this difference did not
reach statistical significance. Heilmann et al. [24] previ-
ously reported significant upregulation of fecal S100A12
concentration in dogs with CE compared with healthy
Beagles, which is consistent with our results in the duode-
num and colon.
We found a significant association between colonic mu-
cosal S100A12 concentrations and the severity of epithe-
lial injury and total histopathological injury in dogs with
CE. When S100A12 binds to RAGE, an inflammatory re-
sponse occurs due to the production of pro-inflammatory
cytokines via activation of NF-κB, which ultimately leads
to tissue damage [9–11]. In the current study, we found
higher mucosal S100A12 concentrations if the inflamma-
tory infiltrate had a neutrophil or macrophage component.
This is consistent with the findings in human patients
with IBD [14]. However, since only 3 dogs had mild
macrophage infiltration, the results should not be over
interpreted and rather be a sign that more research needs
to be performed with macrophage specific staining. In
dogs with CE, however, Heilmann et al. [24] did not
observe a significant association between fecal S100A12
and the presence of neutrophils and macrophages in intes-
tinal mucosal biopsies or with the site(s) of inflammatory
lesions. It is challenging to correlate fecal S100A12
concentrations to the site(s) of inflammatory lesions and
cellular infiltrates within the GI tract, as it is unclear from
which part of the intestine the S100A12 protein originates.
Fecal S100A12 can be considered as reflective for mucosal
S100A12 concentration giving an indication for the need
to localize the site of the inflammatory lesions within the
GI tract and to identify the areas most affected by the dis-
ease process. In addition to standard histology, mucosal
Table 2 Mucosal S100A12 and MPO levels in relation to histopathologic changes in the colon and cecum (Continued)
Histopathological findings n Severity groups S100A12 (μg/L)
Median (IQR)
P valuea MPO (ΔA/min)
Median (IQR)
P valuea
Lamina propria eosinophils 6 Normal (n = 3) 34.02 (8.62-249.74) 0.2181 0.37 (0.12-1.66) 0.4642
Mild (n = 3) 351.79 (71.02-405.48) 0.97 (0.4-1.51)
Lamina propria neutrophils 6 Normal (n = 5) 71.02 (8.62-405.48) 0.4075 0.68 (0.12-1.66) 0.3664
Moderate (n = 1) 351.79 1.51
Lamina propria macrophage 6 Normal (n = 6) 160.38 (8.62-405.48) – 0.68 (0.12-1.66) –
Association between mucosal S100A12 concentrations and MPO activities with severity of histopathological findings in the colon and cecum of dogs with CE.
Statistical differences were calculated based on the log-transformed values of S100A12 and MPO. Untransformed values are reported as median (IQR)
n sample size, IQR interquartile range, LPC lymphocytes/plasma cells
aANOVA test after logarithmic transformation of original values
bstatistically significant association
Table 3 Clinical outcome related to CIBDAI score before / after treatment in CE dogs
Clinical outcome Number of dogs CIBDAI before treatment Median (range) CIBDAI after treatment Median (range)
Food-responsive enteropathy (FRE) 10 4 (2-9) 0 (0-1)
Antibiotic-responsive enteropathy (ARE) 4 5.5 (1-6) 0 (0-0)
Steroid-responsive enteropathy (SRE) 13 4 (0-7) 0 (0-1)
Steroid non-responsive enteropathy (SNRE) 3 7 (4-9) 9 (4-10)
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biomarkers could provide valuable information concern-
ing localization, severity and possible pathogenesis of in-
flammatory processes.
In our study, mucosal MPO activity was significantly
higher in all studied segments of the intestine of dogs with
CE than the corresponding activity in healthy Beagles.
Similar results were also observed in the colonic mucosa
of humans with IBD [31–34] and in animal models of
human IBD [35–37]. In addition to the bactericidal
activity of MPO products in activated phagocytes, there is
considerable evidence that inappropriate or excessive
stimulation of oxidant formation by this enzyme can
result in host tissue damage [45]. In the present study,
mucosal MPO activity showed a significant association
with severity of epithelial injury and total histopathological
injury in the duodenum of dogs with CE, which is consist-
ent with findings in humans with IBD [32, 33] and also in
animal models of human IBD [37]. The most severe histo-
pathological injuries observed in mucosal samples with
higher MPO activity could be explained by MPO-induced
oxidative tissue damage in the inflamed mucosa. In
addition, mucosal MPO activity showed a significant
association only with eosinophil infiltration but not with
neutrophil infiltration in the duodenum. In future studies,
immunohistochemistry can be used to localize S100A12
and MPO cellular origin more specifically in the intestinal
mucosa of dogs with CE.
We did not find a significant association between
mucosal S100A12 concentrations or MPO activities in
each intestinal segment with CIBDAI score before treat-
ment or CE type (ie, FRE, ARE, SRE, or SNRE). Similar
to our findings, mucosal S100A12 concentrations were
not associated with the pediatric Crohn’s disease activity
index (PCDAI) in children with IBD [18]. However,
these findings contrast with the study of Heilmann et al.
[24], who found a significant correlation between fecal
S100A12 and the canine chronic enteropathy clinical
activity index (CCECAI). It should be taken into consid-
eration that CIBDAI or CCECAI include a number of
subjective elements and consequently do not always
represent the actual inflammatory burden, which may
lead to discordance between the results of our study
with others. In contrast to our results, another study by
Heilmann et al. [26] revealed elevated fecal S100A12
concentrations in dogs with SRD compared with those
with FRD or ARD. Elevated fecal S100A12 concentra-
tions were also observed in SNRD dogs compared with
those in dogs that underwent complete remission [26].
One of the limitations of our study is that we did not
measure S100A12 concentrations in the feces of dogs
with CE to assess for any associations between fecal
S100A12 concentrations and types of clinical outcome.
Accordingly, direct comparisons between our results
and those with of Heilmann et al. [26] are not possible.
One possible reason why a significant association between
these biomarkers and clinical outcome was not observed
might be the small number of samples from dogs with a
certain clinical outcome (especially SNRE dogs, n = 3).
Also the comparison between intestinal segments led to
rather low case numbers when assessing the association
between mucosal S100A12 concentrations and MPO
activities with the type of clinical outcome. Another limi-
tation is that the treatment follow up was not standardized
in our study which should be considered when planning
future studies.
Duodenal S100A12 concentrations were higher in four
hypoalbuminemic dogs with CE. However, due to the low
number of hypoalbuminemic dogs in our study, the clinical
significance of our results is not clear. Heilmann et al. did
not find a significant association between fecal S100A12
concentrations and hypoalbuminemia (< 20 g/L) in dogs
with CE despite numerically higher fecal S100A12 concen-
trations in dogs with hypoalbuminemia [24]. Our findings
suggest that further studies are warranted in more severely
affected patients and should include measurements of both
fecal and mucosal S100A12 concentrations.
We observed a moderate positive correlation between
mucosal S100A12 concentrations and MPO activities in
dogs with CE and healthy Beagles combined and also in
healthy Beagles alone. However, no correlation was found
in dogs with CE alone and also when analyzing different
intestinal segments of dogs with CE. In pediatric studies, a
moderate positive correlation was found between mucosal
S100A12 and calprotectin concentrations only in non-IBD
controls but not in patients with IBD [18]. Given that both
S100A12 and MPO are derived predominantly from neu-
trophils, a correlation between the two biomarkers in dogs
with CE was expected. Possible reasons for not having this
correlation could be that two different methods were used
to measure S100A12 concentrations and MPO activities
and different functional pathways of these biomarkers in
intestinal inflammation.
In the present study, we used stored intestinal mucosal
samples from both diseased and healthy Beagle dogs. In the
case of healthy Beagle dogs, the samples were collected
during post-mortem examinations after finishing other
non-related studies to avoid the unnecessary use of labora-
tory animals for experimental proposes. This methodology
complies with the principles of replacement, reduction and
refinement of animal experiments [46]. As this approach
requires long-term stability of the measured analytes, we
checked the MPO activity in 14 randomly chosen mucosal
supernatant samples before and after 3 years of storage at
− 80 °C. The median (range) of MPO activity at the first
measurement (0.35 ΔA/min (0.01-1.92)) and after 3 years
of storage at − 80 °C (0.35 ΔA/min (0.004-2.19)) were not
statistically different (P = 0.101), which shows long-term
stability of MPO activity in mucosal supernatant samples.
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Concentrations of S100A12 in fecal extracts stored frozen
at − 80 °C have also been shown to be stable for years
(Heilmann RM, unpublished data) and it is reasonable to
assume that the same holds true for mucosal specimens. In
addition, in our study, the control dogs were intact and
older Beagles, however, it is rather unlikely that breed,
gender, age, or being castrated or intact has an influence on
our results. Age had also no influence on colonic mucosal
MPO activity in baboons [47].
Conclusions
This study showed that both mucosal S100A12 concentra-
tions and MPO activities are increased in the in the duode-
num and colon of dogs with CE compared with healthy
Beagles; mucosal MPO activity is also increased in the
ileum and cecum. In dogs with CE, mucosal S100A12 con-
centrations correlated with the severity of epithelial injury
and total histopathological injury in the colon. Mucosal
MPO activity is associated with the severity of epithelial
injury and total histopathological injury in the duodenum
of dogs with CE. The results provide supporting evidence
for mucosal S100A12 and MPO as potential diagnostic bio-
markers in dogs with CE. Further prospective research is
needed to assess the value of measuring mucosal S100A12
concentrations and MPO activities in clinical practice, the
relationship between mucosal and fecal S100A12 and
MPO, and other inflammatory markers in dogs with CE.
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